Management of Asplenic Pediatric Patients with Hematologic Abnormalities

Diagnostic Evaluation (First 48 h)

• Obtain a peripheral blood smear reviewed by a hematopathologist to look for blasts, abnormal white‑cell morphology, red‑cell poikilocytosis, schistocytes, or giant platelets. 1
• Repeat a complete blood count with differential to confirm absolute neutrophil, lymphocyte, eosinophil counts and hemoglobin level. 1
• Order coagulation studies (PT, aPTT) to exclude concurrent clotting disorders. 1
• Measure serum lactate dehydrogenase and uric acid when leukemia is suspected. 1
• Perform a basic metabolic panel and liver function tests to screen for tumor‑lysis syndrome or organ dysfunction. 1

Bone‑Marrow Assessment

• Proceed immediately to bone‑marrow aspiration and biopsy when the peripheral smear shows atypical or immature cells, or when more than one hematologic cell line is abnormal. 1
• Conduct bone‑marrow morphologic examination, flow cytometry, karyotyping, and molecular testing for fusion genes and mutations. 1
• Perform BCR::ABL1 testing (quantitative PCR or FISH) to exclude chronic myeloid leukemia. 1
• Test for core‑binding‑factor abnormalities (e.g., RUNX1‑RUNX1T1, CBFB‑MYH11, PML‑RARA, MLL rearrangements) because AML subtypes with these lesions may present with cytopenias and eosinophilia. 1
• Do not delay bone‑marrow examination; multi‑lineage abnormalities mandate direct marrow assessment. 1

Immediate Clinical Stability Assessment

Infection Risk in Asplenic Children

• Hospitalize immediately if severe neutropenia (ANC < 500 µL⁻¹) is present, especially when fever or bleeding occurs. 1
• Recognize that asplenia markedly increases the risk of overwhelming post‑splenectomy infection from encapsulated organisms (Streptococcus pneumoniae, Haemophilus influenzae type B, Neisseria meningitidis). 2
• Provide appropriate antimicrobial prophylaxis for asplenic patients. 1
• Ensure vaccination status is current for pneumococcal, Haemophilus influenzae type B, and meningococcal vaccines. 2
• Supply an emergency antibiotic regimen (e.g., amoxicillin 50 mg/kg three times daily) for sudden onset of fever, malaise, or chills. 2
• Clinical deterioration can be rapid even after antibiotic administration in asplenic patients with infection. 2

Bleeding and Platelet Management

• Assess for petechiae, purpura, mucosal bleeding, or signs of intracranial hemorrhage. 1
• Reserve platelet transfusion for active bleeding or platelet counts < 10,000 µL⁻¹ in the setting of high bleeding risk. 1
• Interpret low mean platelet volume as a possible marker of platelet dysfunction or consumption. 1

Supportive Care Pending Diagnosis

• Restrict high‑risk activities (contact sports or activities with head‑trauma potential). 1
• Educate caregivers to watch for persistent fever, worsening bleeding, altered mental status, or severe headache. 1

Critical Pitfalls to Avoid

• Do not attribute findings solely to viral infection or reactive thrombocytosis without peripheral‑smear review; early leukemia can be missed. 1
• Do not initiate empiric corticosteroids before a definitive diagnosis, as steroids may obscure leukemic cells. 1
• Do not assume a benign reactive thrombocytosis when lymphocytosis, eosinophilia, and low MPV are present. 1
• Bone‑marrow examination is unnecessary in children with typical immune thrombocytopenia (isolated thrombocytopenia with bruising/bleeding). 3

Differential Diagnosis Highlights

• Acute myeloid leukemia with core‑binding‑factor abnormalities may present with cytopenias and eosinophilia; requires comprehensive marrow studies. 1
• Chronic myeloid leukemia can present with variable counts and eosinophilia; BCR::ABL1 testing is essential. 1

Infection Prevention and Management in Asplenic Children

Risk of Overwhelming Infection

• Asplenia markedly increases the risk of overwhelming post‑splenectomy infection from encapsulated organisms such as Streptococcus pneumoniae, Haemophilus influenzae type B, and Neisseria meningitidis 4.
• The risk of fatal serious infection persists lifelong, with documented cases of fulminant infection occurring more than 20 years after splenectomy 4.

Prophylactic Antibiotic Therapy

• Lifelong prophylactic oral phenoxymethylpenicillin (or erythromycin for penicillin‑allergic patients) is recommended for all asplenic individuals, particularly during the first two years after splenectomy 4.

Vaccination Strategy

• Vaccination status should be up‑to‑date for pneumococcal disease (13‑valent conjugate vaccine followed by the 23‑valent polysaccharide vaccine), Haemophilus influenzae type B, and meningococcal disease 4.
• Re‑immunization is advised after two years for patients who remain at risk, especially children younger than two years of age 4.